Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2mg dienogest/30µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive.

Abstract

To evaluate the effects of a continuous regimen combined oral contraceptive (COC) containing 2mg dienogest and 30µg ethinyl estradiol (DNG/EE) compared to a 21/7 regimen on the quality of life (QoL) and sexual function in women affected by endometriosis-associated pelvic pain. Sixty-three women constituted the Study group treated with DNG/EE COC continuous regimen; 33 women were given DNG/EE COC in a 21/7 regimen. To define the endometriosis-associated pelvic pain, the Visual Analogic Scale was used. The Short Form-36, Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess QoL, sexual function and sexual distress, respectively. The study included two follow-ups. At 3 and 6months of treatment there was an improvement in pain of the Study group (p<0.001). The Control group underwent pain improvement at the second follow-up (p<0.05). At the first and the second follow-ups, the Study group reported QoL improvements in all categories (p<0.001). The Control group reported QoL improvements in all categories at the second follow-up (p<0.05). At the first and the second follow-ups of the Study group, the FSFI total score had risen (p<0.001), and the FSDS score had dropped (p<0.001). An improvement of the FSFI score and a reduction of the FSDS score of the Control group was observed at the second follow-up (p<0.001), but not at the first follow-up (p=NS). Women on DNG/EE COC continuous regimen reported a reduction of endometriosis-associated pelvic pain and there was an improvement of their sexual activity and their QoL that was better than the DNG/EE 21/7 conventional regimen.